The purpose of this study is to test the safety of an investigational drug called CFI-402411
alone and in combination with pembrolizumab and to study its effects in patients with
advanced solid tumors who have progressed following previous therapies.
This study will be a first-in-human study evaluating the safety and tolerability of
CFI-402411 in subjects with advanced solid malignancies, when CFI-402411 is administered as a
single agent or in combination with pembrolizumab. CFI-402411 is an oral pill that blocks the
function of HPK1. Blocking HPK1 could stimulate an immune response against the tumor in
patients. This immune response could be further enhanced when combined with pembrolizumab.
The data obtained from this study will determine the dose and schedule and subject selection
for further clinical studies.
Pre-clinical findings support further development of CFI-402411 as a novel anti-cancer agent,
and the combination of CFI-402411 with pembrolizumab as a potential strategy to improve
outcomes of subjects with advanced malignancies.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.